Athira Pharma Inc (NAS:ATHA)
$ 0.5499 0.0114 (2.12%) Market Cap: 21.26 Mil Enterprise Value: -46.72 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 36/100

Athira Pharma Inc at JMP Securities Life Sciences Conference Transcript

May 15, 2023 / 02:30PM GMT
Release Date Price: $2.87 (-2.71%)
Jason Butler
JMP Securities LLC - Analyst

[Thank you, everybody], for joining us this morning at the JMP Securities Life Science Conference. Excited to be joined next by Athira Pharma with Mark Litton, the company's CEO; and Hans Moebius, the company's Chief Medical Officer.

Thank you, Hans and Mark, for being here, another exciting year for Athira. You're focused on a novel class of drugs for broadly neurodegenerative diseases. I guess, with that, I'll turn it over to you, Mark, just to give a quick overview of the company, and we'll go from there.

Mark Litton
Athira Pharma, Inc. - President, CEO, & Director

Great. Thank you, Jason, for inviting us. Thank you all for coming to hear our chat. For those of you who don't know us, Athira is a late-stage biotech company. We're focused completely on neurodegeneration. We've spent many, many years identifying small molecules that enhance a natural repair mechanism or the HGF/MET system.

And HGF/MET has been known for decades. Really, it's very important for neuronal health, neuroprotection,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot